BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 2, 2005
View Archived Issues
BioMarin's Second MPS Drug, Naglazyme, Approved By FDA
BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today)
Read More
Hybridon, Novartis In $136M Agreement For TLR9 Drugs
Read More
Affymetrix Buys Out Partner ParAllele: $120M Stock Deal
Read More
Intra-Cellular Paying BMS For License To CNS Drugs
Read More
Other News To Note
Read More